EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE

Objectives: To determine the frequency of early molecular response in patients of chronic myeloid leukemia treated with Imatinib and its association with baseline white blood cell (WBC) count and spleen size. Study Design: Cross sectional study. Place and Duration of Study: Combined Military Hosp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abdul Ali Wajid, Mansoor Zeeshan, Faisal Mehmood, Imtenan Sharif, Muhammad Umair, Aamira Ali
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2018
Materias:	chronic myeloid leukemia imatinib Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/d08677138f37425ea0848e8e5bae5e9c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d08677138f37425ea0848e8e5bae5e9c
record_format	dspace
spelling	oai:doaj.org-article:d08677138f37425ea0848e8e5bae5e9c2021-12-02T03:15:22ZEARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE0030-96482411-8842https://doaj.org/article/d08677138f37425ea0848e8e5bae5e9c2018-10-01T00:00:00Zhttps://www.pafmj.org/index.php/PAFMJ/article/view/2291/1987https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objectives: To determine the frequency of early molecular response in patients of chronic myeloid leukemia treated with Imatinib and its association with baseline white blood cell (WBC) count and spleen size. Study Design: Cross sectional study. Place and Duration of Study: Combined Military Hospital, Rawalpindi Pakistan, from May to Nov 2017. Material and Methods: Seventy eight patients of Chronic Myeloid Leukemia (CML) in chronic phase (CP) were included in the study. Inclusion criteria were: 18 years or older, diagnosed with CML in CP with positive BCR ABL1. Patients who were in accelerated/blast phase, or already taking any Tyrosine Kinase Inhibitors or chemotherapy were excluded from the study. Base line WBC count, spleen size and BCR-ABL1 IS values were recorded. All the enrolled patients were placed on Imatinib therapy (400 mg/day) and RT-PCR for BCR ABL1 transcript was repeated after three months. Results: In our study, 60.15% of patients achieved EMR at 3 months after Imatanib therapy (p-value <0.001). In univariate analysis, there was significant association of spleen size, baseline WBC count and percentages of blasts in bone marrow with BCR ABL1 (IS) at 3 months (p-value <0.001), while on multivariate regression model, significant association was found only in spleen size (p-value <0.001) with EMR. Conclusion: A significant number of patients achieved EMR with Imatinib therapy. Spleen size at diagnosis was the only significant factor associated with achieving EMR. It is imperative to identify patients at an early stage who are unlikely to achieve EMR and therefore have poor over-all survival.Abdul Ali WajidMansoor ZeeshanFaisal MehmoodImtenan SharifMuhammad UmairAamira AliArmy Medical College Rawalpindiarticlechronic myeloid leukemiaimatinibMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 68, Iss 5, Pp 1199-1204 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	chronic myeloid leukemia imatinib Medicine R Medicine (General) R5-920
spellingShingle	chronic myeloid leukemia imatinib Medicine R Medicine (General) R5-920 Abdul Ali Wajid Mansoor Zeeshan Faisal Mehmood Imtenan Sharif Muhammad Umair Aamira Ali EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE
description	Objectives: To determine the frequency of early molecular response in patients of chronic myeloid leukemia treated with Imatinib and its association with baseline white blood cell (WBC) count and spleen size. Study Design: Cross sectional study. Place and Duration of Study: Combined Military Hospital, Rawalpindi Pakistan, from May to Nov 2017. Material and Methods: Seventy eight patients of Chronic Myeloid Leukemia (CML) in chronic phase (CP) were included in the study. Inclusion criteria were: 18 years or older, diagnosed with CML in CP with positive BCR ABL1. Patients who were in accelerated/blast phase, or already taking any Tyrosine Kinase Inhibitors or chemotherapy were excluded from the study. Base line WBC count, spleen size and BCR-ABL1 IS values were recorded. All the enrolled patients were placed on Imatinib therapy (400 mg/day) and RT-PCR for BCR ABL1 transcript was repeated after three months. Results: In our study, 60.15% of patients achieved EMR at 3 months after Imatanib therapy (p-value <0.001). In univariate analysis, there was significant association of spleen size, baseline WBC count and percentages of blasts in bone marrow with BCR ABL1 (IS) at 3 months (p-value <0.001), while on multivariate regression model, significant association was found only in spleen size (p-value <0.001) with EMR. Conclusion: A significant number of patients achieved EMR with Imatinib therapy. Spleen size at diagnosis was the only significant factor associated with achieving EMR. It is imperative to identify patients at an early stage who are unlikely to achieve EMR and therefore have poor over-all survival.
format	article
author	Abdul Ali Wajid Mansoor Zeeshan Faisal Mehmood Imtenan Sharif Muhammad Umair Aamira Ali
author_facet	Abdul Ali Wajid Mansoor Zeeshan Faisal Mehmood Imtenan Sharif Muhammad Umair Aamira Ali
author_sort	Abdul Ali Wajid
title	EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE
title_short	EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE
title_full	EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE
title_fullStr	EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE
title_full_unstemmed	EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE
title_sort	early molecular response with imatinib therapy in chronic myeloid leukemia and its association with baseline white blood cell count and spleen size
publisher	Army Medical College Rawalpindi
publishDate	2018
url	https://doaj.org/article/d08677138f37425ea0848e8e5bae5e9c
work_keys_str_mv	AT abdulaliwajid earlymolecularresponsewithimatinibtherapyinchronicmyeloidleukemiaanditsassociationwithbaselinewhitebloodcellcountandspleensize AT mansoorzeeshan earlymolecularresponsewithimatinibtherapyinchronicmyeloidleukemiaanditsassociationwithbaselinewhitebloodcellcountandspleensize AT faisalmehmood earlymolecularresponsewithimatinibtherapyinchronicmyeloidleukemiaanditsassociationwithbaselinewhitebloodcellcountandspleensize AT imtenansharif earlymolecularresponsewithimatinibtherapyinchronicmyeloidleukemiaanditsassociationwithbaselinewhitebloodcellcountandspleensize AT muhammadumair earlymolecularresponsewithimatinibtherapyinchronicmyeloidleukemiaanditsassociationwithbaselinewhitebloodcellcountandspleensize AT aamiraali earlymolecularresponsewithimatinibtherapyinchronicmyeloidleukemiaanditsassociationwithbaselinewhitebloodcellcountandspleensize
_version_	1718401886517723136

EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE

Ejemplares similares